AAV with unique capsid protein VP1 and methods of using for treatment
The invention provides an adeno-associated viral (AAV) vector comprising a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence, and wherein the heterologous nucleic acid sequence can encode the NGF-PTH fusion polypeptide or methylmalonyl CoA mutase enzyme. The invention also provides a polypeptide comprising nerve growth factor (NGF) signal peptide and parathyroid hormone (PTH), wherein the polypeptide can comprise, consist essentially of, or consist of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. The invention provides a nucleic acid encoding the polypeptide, a vector comprising the nucleic acid, and a composition comprising the polypeptide, nucleic acid, or vector, as well as treatment methods comprising the polypeptide, nucleic acid, vector, or composition. The invention further provides a method of treating methylmalonic acidaemia (MMA) in a mammal comprising administering an AAV vector comprising a heterologous nucleic acid sequence encoding methylmalonyl CoA mutase enzyme to the mammal.
1. An adeno-associated viral (AAV) vector comprising a nucleic acid encoding a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence.
2. The AAV vector of claim 1 , wherein the heterologous nucleic acid sequence is operably linked to regulatory sequences which direct its expression in a host cell.
3. The AAV vector of claim 1 , wherein the heterologous nucleic acid sequence is flanked by one or more inverted terminal repeat (ITR) sequences.
4. The AAV vector of claim 1 , wherein the nucleic acid encoding the capsid comprises the nucleic acid sequence of SEQ ID NO: 5.
5. The AAV vector of claim 1 , wherein the heterologous nucleic acid sequence encodes methylmalonyl CoA mutase enzyme.
6. A method of treating methylmalonic acidaemia (MMA) in a mammal with MMA comprising intravenously administering to the mammal the vector of claim 5 , thereby treating MMA in the mammal.
7. The AAV vector of claim 1 , wherein the heterologous nucleic acid sequence encodes a polypeptide comprising nerve growth factor (NGF) signal peptide and parathyroid hormone (PTH).
8. The AAV vector of claim 7 , wherein the polypeptide comprises the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2.
9. A method of treating hypoparathyroidism in a mammal comprising administering the AAV vector of claim 7 to the salivary glands of the mammal, thereby treating hypoparathyroidism in the mammal.
10. A composition comprising the AAV vector of claim 1 and a pharmaceutically acceptable carrier.
11. The vector of claim 1 , wherein the adeno-associated viral vector comprises a nucleic acid encoding a capsid protein (i) comprising the amino acid sequence of SEQ ID NO: 4 or (ii) encoded by the nucleic acid sequence of SEQ ID NO: 5.
12. The vector of claim 1 , wherein the adeno-associated viral vector comprises a nucleic acid encoding a capsid protein comprising the amino acid sequence of SEQ ID NO: 9.